Healthcare / Drug Manufacturers - GeneralUpdated 2026-05-10 22:07 UTC

BCBA/LLY stock hub

BCBA/LLY has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BCBA/LLYis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1177.9T

Buenos Aires Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

BCBA/LLY

In the news

Latest news · BCBA/LLY

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E25.4

P25 14.1P50 17.9P75 19.4

Trailing P/E33.7

P25 25P50 30P75 39

ROE107.5

P25 6.8P50 15.6P75 45.1

ROIC41.9

P25 9P50 19.1P75 21.2

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BCBA/LLY market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

228

Groups with data

Currency

USD

Showing 228 of 228 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	AR
Employees	50,000
Employees Change	3,000%
Employees Change Percent	6.38
Enterprise value	ARS 1230.3T
Exchange	Buenos Aires Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Drug Manufacturers - General
Last refreshed	2026-05-10
Market cap	ARS 1177.9T
Price	ARS 25,240
Price currency	ARS
Rev Per Employee	1,996,259,666.23x
Sector	Healthcare
Sic	2834
Symbol	bcba/LLY
Website	https://www.lilly.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.96%
EV Earnings	35.23x
EV/EBIT	25.85x
EV/EBITDA	24.25x
EV/FCF	75.32x
EV/Sales	12.23x
FCF yield	1.39%
Forward P/E	25.41x
P/B ratio	27.33x
P/E ratio	33.73x
P/S ratio	11.8x
PE Ratio10 Y	52.61x
PE Ratio3 Y	73.78x
PE Ratio5 Y	62.71x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	47.3%
EBITDA Margin	50.13%
FCF margin	16.36%
Gross margin	82.83%
Gross Profit	ARS 82.7T
Gross Profit Growth	49.48%
Gross Profit Growth Q	54.44%
Gross Profit Growth3 Y	40.65%
Gross Profit Growth5 Y	25.35%
Net Income	ARS 34.9T
Net Income Growth	127.6%
Net Income Growth Q	168.07%
Net Income Growth3 Y	64.42%
Net Income Growth5 Y	32.92%
Pretax Margin	43.08%
Profit Margin	34.99%
Profit Per Employee	ARS 698.4M
ROA	20.74
Roa5y	13.51
ROCE	42.75
ROE	107.5
Roe5y	74.21
ROIC	41.92
Roic5y	35.51

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	56.65%
Cagr3y	93.8%
Cagr5y	115.5%
Div CAGR10	81.92%
Div CAGR3	137.09%
Div CAGR5	113.79%
EPS Growth	129.1
EPS Growth Q	169.9
EPS Growth3 Y	64.8
EPS Growth5 Y	33.34
FCF Growth	216.44%
FCF Growth Q	1,827.56%
FCF Growth3 Y	36.63%
FCF Growth5 Y	13.11%
OCF Growth	119.79%
OCF Growth Q	220.11%
OCF Growth10 Y	21.88%
OCF Growth3 Y	44.46%
OCF Growth5 Y	21.25%
Revenue Growth	47.44x
Revenue Growth Q	55.54x
Revenue Growth3 Y	37.67x
Revenue Growth5 Y	23.17x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	ARS 0.7
Assets	ARS 161.1T
Cash	ARS 7.3T
Current Assets	ARS 76.7T
Current Liabilities	ARS 51.2T
Debt	ARS 59.9T
Debt EBITDA	ARS 1.19
Debt Equity	ARS 1.39
Debt FCF	ARS 3.67
Equity	ARS 43.1T
Interest Coverage	388.3
Liabilities	ARS 118T
Long Term Assets	ARS 84.4T
Long Term Liabilities	ARS 66.7T
Net Cash	ARS -52T
Net Cash By Market Cap	ARS -4.41
Net Debt EBITDA	ARS 1.04
Net Debt Equity	ARS 1.21
Net Debt FCF	ARS 3.18
Tangible Book Value	ARS 24.4T
Tangible Book Value Per Share	ARS 27,358
WACC	6.57

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.5
Inventory Turnover	1.04
Net Working Capital	ARS 23.4T
Quick ratio	0.72
Working Capital	ARS 25.1T
Working Capital Turnover	ARS 6,791

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.57%
Dividend Growth	55.6%
Dividend Growth Years	23%
Dividend per share	ARS 92.34
Dividend Years	27
Dividend Yield	0.37%
Ex Div Date	2026-02-13
Last Dividend	ARS 27.22
Payout Frequency	Quarterly
Payout Ratio	0.24%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	56.6%
200-day SMA	23,920.5
3Y total return	628.23%
50-day SMA	24,933.2
50-day SMA vs 200-day SMA	50over200
5Y total return	4,545.69%
All Time High	31,100
All Time High Change	-18.84%
All Time High Date	2026-01-08
All Time Low	328.6
All Time Low Change	7,581.75%
All Time Low Date	2020-11-03
ATR	820.3
Beta	0.48
Ch YTD	-14.09
High	26,120
High52	31,100
High52 Date	2026-01-08
High52ch	-18.84%
Low	25,160
Low52	14,500
Low52 Date	2025-05-26
Low52ch	74.07%
Ma50ch	1.23%
Price vs 200-day SMA	5.52%
RSI	53.52
RSI Monthly	62.5
RSI Weekly	50.73
Sharpe ratio	0.79x
Sortino ratio	1.26
Total Return	0.94%
Tr YTD	-13.96
Tr1m	2.39%
Tr1w	-2.7%
Tr3m	-10.16%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	ARS 47.2T
Operating Income Growth	74.29
Operating Income Growth Q	84.42
Operating Income Growth3 Y	64.3
Operating Income Growth5 Y	36.9
Operating margin	47.3

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	889,347,313%
Net Borrowing	6,243,608,941,488
Shares Insiders	0.17%
Shares Institutions	90.92%
Shares Qo Q	-0.23%
Shares Yo Y	-0.57%
Short Ratio	2.62

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	ARS 15.5T
Average Volume	12,531x
Bv Per Share	48,237.8
CAPEX	ARS -12T
Ch1m	2.39
Ch1w	-2.7
Ch1y	55.8
Ch3m	-10.31
Ch3y	620.1
Ch5y	4,453
Ch6m	4.64
Change	-2.25%
Change From Open	-2.77
Close	25,820
Days Gap	0.54
Depreciation Amortization	2,857,458,124,431
Dollar Volume	280,996,920
Earnings Date	2026-04-30
EBIT	ARS 47.2T
EBITDA	ARS 50T
EPS	ARS 38,891
F Score	6
FCF	ARS 16.3T
FCF EV Yield	1.33x
Financing CF	-9,757,631,263,100
Fiscal Year End	December
Founded	1,876
Goodwill	8,573,773,031,210
Graham Number	3943.21991
Graham Upside	-84.38
Income Tax	ARS 8.1T
Investing CF	-15,935,760,529,500
Is Primary Listing	0
Last Earnings Date	2026-04-30
Last Report Date	2026-03-31
Last Split Date	2024-01-24
Last Split Type	Forward
Lynch Fair Value	ARS 18,707
Lynch Upside	-25.88
Ma150	25,907.2
Ma150ch	-2.58%
Ma20	24,432
Ma20ch	3.31%
Net CF	3,024,133,489,300
Open	25,960
P FCF Ratio	72.12
P OCF Ratio	41.63
Payment Date	2026-03-10
Position In Range	8.33
Ppne	37,120,381,117,180
Price Date	2026-05-08
Price EBITDA	ARS 23.54
Ptbv Ratio	48.19
Relative Volume	0.89x
Revenue	99,812,983,311,300x
SBC By Revenue	0.88x
Share Based Comp	874,498,172,100
Tax By Revenue	8.09x
Tax Rate	18.79%
Tr6m	4.9%
Volume	11,133
Z Score	7.62

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

BCBA/LLY dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.4%

$92.3 annual per share

Payout ratio

+0.2%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+113.8%

23 consecutive years of growth

Total shareholder yield

+0.9%

Next ex-dividend date: 2026-02-13

Performance

BCBA/LLY stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BCBA/LLY?

Insider, institutional, and short-interest positioning.

Institutional ownership

+90.9%

Share of float held by funds and institutions

Insider ownership

+0.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

BCBA/LLY momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

53.5

Neutral momentum band

Price vs 200-day MA

+5.5%

50/200-day relationship not available

Beta (5Y)

0.48

Less volatile than the market

Sharpe ratio

0.79

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BCBA/LLY

Hub-level FAQ points readers to the deeper analysis pages.

What is the current bcba/LLY stock rating?

bcba/LLY is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full bcba/LLY analysis?

The full report lives at /stocks/bcba/LLY/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for bcba/LLY?

The latest report frames bcba/LLY around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the bcba/LLY page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.